|
WO2021043757A1
|
|
Factor viii protein with increased half-life
|
|
EP3785726A1
|
|
Factor viii protein with increased half-life
|
|
EP3747903A1
|
|
Method and kit for testing potency of immunoglobulin compositions
|
|
EP3736286A1
|
|
Single chain factor viii molecule
|
|
CA3097943A1
|
|
De-immunized factor viii molecule and pharmaceutical compositions comprising the same
|
|
WO2019072566A1
|
|
Combination of anti-il10 and anti-pd1 antibodies in cancer treatment
|
|
AU2017233923A1
|
|
Treatment of severe Community Acquired Pneumonia
|
|
EP3275897A1
|
|
Process for preparing immunoglobulin compositions
|
|
AU2013204492A1
|
|
Immunoconjugates targeting CD138 and uses thereof
|
|
AU2013203245A1
|
|
Agents targeting CD138 and uses thereof
|
|
AU2013201618A1
|
|
Uses of immunoconjugates targeting CD138
|
|
AU2012372140A1
|
|
Uses of immunoconjugates targeting CD138
|
|
MX2012006198A
|
|
Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle).
|
|
RU2561041C2
|
|
Applications of immunoconjugates with cd138 as target
|
|
GB201006753D0
|
|
Process for preparing an immunolobulin composition
|
|
GB0920933D0
|
|
Agent for treating disease
|
|
GB0920944D0
|
|
Agents for treating disease
|
|
GB0920942D0
|
|
Agent for treating disease
|
|
GB0920940D0
|
|
Agent for treating disease
|
|
NZ603751A
|
|
Composition for treating disease
|
